Medirom Healthcare Technologies Inc. is facing a significant challenge as it has received a notice from Nasdaq regarding potential delisting. The company failed to file its Annual Report on Form 20-F for the year ending December 31, 2025, within the extension period granted by Nasdaq. This failure to comply with Nasdaq Listing Rule 5250(c)(1) raises concerns about the company's future on the exchange.

The situation is critical for Medirom, as the notice states that unless the company requests an appeal, trading of its American Depositary Shares (ADSs) will be suspended and delisted from Nasdaq starting November 24, 2026. On November 18, 2026, Medirom submitted a timely request for a hearing before a Nasdaq Hearings Panel to appeal this determination. This request automatically stays any suspension of trading for 15 days, providing the company a brief respite as it navigates this issue.

Background

Medirom Healthcare Technologies Inc. is a company listed on the Nasdaq under the ticker symbol MRM. It operates within the personal services sector, as classified under the Standard Industrial Classification (SIC) code 7200. The company is incorporated in Japan and has been actively filing reports with the SEC, including recent filings such as a 20-F and several 6-K forms.

What the Filing Says

According to the filing dated November 18, 2026, Medirom received a notice from Nasdaq on November 13, 2026, indicating that it had not regained compliance with the exchange's listing rules. The notice specifically mentioned that the company had not filed its Annual Report within the extended compliance period. The company had previously been notified on May 26, 2026, about its non-compliance with the same rule.

The filing states, "The Notice stated that unless the Company requests an appeal of the delisting determination, trading of the Company’s American Depositary Shares will be subject to suspension and delisting from Nasdaq at the opening of business on November 24, 2026." Medirom has also requested an extended stay of any trading suspension pending the outcome of its hearing.

Impact

This situation may affect Medirom's shareholders and investors, as a delisting could significantly impact the company's market presence and liquidity. Additionally, it may set a precedent for other companies in the personal services industry facing similar compliance issues. The outcome of Medirom's appeal could influence how Nasdaq handles future cases of non-compliance.

What's Next

The company has filed its Annual Report with the SEC on the same day it submitted the hearing request. However, there is no assurance that Nasdaq will find this filing sufficient to resolve the compliance issue or that the company will maintain its listing. The filing does not specify what happens next beyond the hearing process.